In 2021, GSK paid Arrowhead Pharmaceuticals $120 million up front for rights to the siRNA drug. Under GSK, GSK4532990 has reached mid-stage clinical development in both MASH and alcohol-related li ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

Biotech company AbbVie (ABBV) said on Wednesday that the U.S. Food and Drug Administration has approved Emrelis medicine for ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

The siRNA technology has has the potential to enable sustained and precise messenger RNA silencing, regulating the expression ...

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...

Innovative delivery techniques, including high-tech nanoparticles and electroporationdevices, may convey more gene therapies ...

Despite a challenging quarter, Codexis Inc (CDXS) focuses on strategic partnerships and technological advancements to drive ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...